Limits...
Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma.

Jiang L, Jiang S, Situ D, Lin Y, Yang H, Li Y, Long H, Zhou Z - Oncotarget (2015)

Bottom Line: We evaluated the association among possible risk factors and survival for metastatic STS by reviewed a single-institution nearly 50-year experience.And patients with monocyte ratio or NLR ratio > 1 should be screened out as candidates for more intensive or aggressive multimodality treatments and more aggressive follow-up.For this reason, this result could serve as a basis for future prospective study.

View Article: PubMed Central - PubMed

Affiliation: Sun Yat-sen University Cancer Center, Guangzhou, China.

ABSTRACT
Metastatic soft tissue sarcomas (STS) represent enormous challenges to improve the low survival rate, which is almost the same as past 2 decades ago. Prognosis of cancer patients are based not only on tumor-related factors but also on host-related factors, particularly systemic inflammatory response. We evaluated the association among possible risk factors and survival for metastatic STS by reviewed a single-institution nearly 50-year experience. We found that both monocyte ratio and NLR ratio were significant prognostic predictors for OS and PFS of metastatic STS. And patients with monocyte ratio or NLR ratio > 1 should be screened out as candidates for more intensive or aggressive multimodality treatments and more aggressive follow-up. For this reason, this result could serve as a basis for future prospective study.

No MeSH data available.


Related in: MedlinePlus

Combining prognostic value of monocyte ratio and NLR ratio on both OS and PFS. PFS progress-free survival, OS overall survival
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496237&req=5

Figure 4: Combining prognostic value of monocyte ratio and NLR ratio on both OS and PFS. PFS progress-free survival, OS overall survival

Mentions: Results of multivariable analysis to identify prognostic factors for OS and PFS in Metastatic STS patients are shown in Table 3. In multivariable analysis, the presence of NLR ratio > 1, and monocyte ratio > 1 were significantly associated with poor prognosis for both OS and PFS (monocyte ratio > 1, hazard ratio 1.999, 95% CI 1.141–3.504, p = 0.016; hazard ratio 1.628, 95% CI 1.080–2.455, p = 0.02, respectively) and (NLR ratio > 1, hazard ratio 2.477, 95% CI 1.423–4.311, p = 0.001; hazard ratio 1.531, 95% CI 1.035–2.265, p = 0.033, respectively). Patients were then divided into four categories according to different monocyte ratio and NLR ratio (group 1, monocyte ratio <= 1 and NLR ratio <= 1 (n = 76, 53.5%); group 2, monocyte ratio <= 1 and NLR ratio > 1 (n = 23, 16.2%); group 3, monocyte ratio > 1 and NLR ratio <= 1 (n = 13, 9.2%); and group 4, monocyte ratio > 1 and NLR ratio > 1 (n = 30, 21.1%)) to evaluate their combining prognostic value on both OS and PFS (Fig. 4). Accordingly, patients in group 1 showed significant better OS than patients in all the other 3 groups.


Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma.

Jiang L, Jiang S, Situ D, Lin Y, Yang H, Li Y, Long H, Zhou Z - Oncotarget (2015)

Combining prognostic value of monocyte ratio and NLR ratio on both OS and PFS. PFS progress-free survival, OS overall survival
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496237&req=5

Figure 4: Combining prognostic value of monocyte ratio and NLR ratio on both OS and PFS. PFS progress-free survival, OS overall survival
Mentions: Results of multivariable analysis to identify prognostic factors for OS and PFS in Metastatic STS patients are shown in Table 3. In multivariable analysis, the presence of NLR ratio > 1, and monocyte ratio > 1 were significantly associated with poor prognosis for both OS and PFS (monocyte ratio > 1, hazard ratio 1.999, 95% CI 1.141–3.504, p = 0.016; hazard ratio 1.628, 95% CI 1.080–2.455, p = 0.02, respectively) and (NLR ratio > 1, hazard ratio 2.477, 95% CI 1.423–4.311, p = 0.001; hazard ratio 1.531, 95% CI 1.035–2.265, p = 0.033, respectively). Patients were then divided into four categories according to different monocyte ratio and NLR ratio (group 1, monocyte ratio <= 1 and NLR ratio <= 1 (n = 76, 53.5%); group 2, monocyte ratio <= 1 and NLR ratio > 1 (n = 23, 16.2%); group 3, monocyte ratio > 1 and NLR ratio <= 1 (n = 13, 9.2%); and group 4, monocyte ratio > 1 and NLR ratio > 1 (n = 30, 21.1%)) to evaluate their combining prognostic value on both OS and PFS (Fig. 4). Accordingly, patients in group 1 showed significant better OS than patients in all the other 3 groups.

Bottom Line: We evaluated the association among possible risk factors and survival for metastatic STS by reviewed a single-institution nearly 50-year experience.And patients with monocyte ratio or NLR ratio > 1 should be screened out as candidates for more intensive or aggressive multimodality treatments and more aggressive follow-up.For this reason, this result could serve as a basis for future prospective study.

View Article: PubMed Central - PubMed

Affiliation: Sun Yat-sen University Cancer Center, Guangzhou, China.

ABSTRACT
Metastatic soft tissue sarcomas (STS) represent enormous challenges to improve the low survival rate, which is almost the same as past 2 decades ago. Prognosis of cancer patients are based not only on tumor-related factors but also on host-related factors, particularly systemic inflammatory response. We evaluated the association among possible risk factors and survival for metastatic STS by reviewed a single-institution nearly 50-year experience. We found that both monocyte ratio and NLR ratio were significant prognostic predictors for OS and PFS of metastatic STS. And patients with monocyte ratio or NLR ratio > 1 should be screened out as candidates for more intensive or aggressive multimodality treatments and more aggressive follow-up. For this reason, this result could serve as a basis for future prospective study.

No MeSH data available.


Related in: MedlinePlus